Gastric bypass hemorraghe
Conditions
Interventions
Patients are randomised between 2 groups: 1) Single dose of 1500 mg TXA, and 2)
Placebo infusion, both to be administered during induction of the procedure by
anaesthesiologist.
Sponsors
Franciscus Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: Primary metabolic procedure; >=18 years; good command of the Dutch or English language.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: Patients unwilling to give informed consent, patients with a medical history of bleeding or VTE (defined as, pulmonary embolism (PE) or deep vein thrombosis (DVT)) and patients who use therapeutic anticoagulants. Patients will also be excluded in case of peroperative arterial bleeding or (iatrogenic) bleeding coming from surrounding organs or vascular structures such as the liver or the spleen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measure is postoperative reintervention (administration of packed red blood cells or, surgical-, radiological-, or endoscopic intervention). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures are the use of haemostatic staple devices and fibrin sealant preoperatively, postoperatively decrease in haemoglobin, increase in heart rate, rates of suspicions of postoperative haemorrhage (i.e. haemorrhage for which extra haemoglobin monitoring and administration of TXA) and rates of VTE, other complications, hospitalization time. | — |
Countries
Netherlands
Outcome results
None listed